Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements

Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements

From: GRACEcast
0 0 4 years ago
Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.

Find us on Facebook